Treatment Satisfaction and Quality of Life With Insulin Glargine Plus Insulin Lispro Compared With NPH Insulin Plus Unmodified Human Insulin in Individuals With Type 1 Diabetes

Abstract

OBJECTIVE -The purpose of this study was to compare quality of life (QoL) and treatment satisfaction using insulin glargine plus insulin lispro with that using NPH insulin plus unmodified human insulin in adults with type 1 diabetes managed with multiple injection regimens.RESEARCH DESIGN AND METHODS -As part of a 32-week, five-center, two-way crossover study in 56 individuals with type 1 diabetes randomized to evening insulin glargine plus mealtime insulin lispro or to NPH insulin (once or twice daily) plus mealtime unmodified human insulin, the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the Audit of Diabetes Dependent Quality of Life questionnaire were completed at baseline and at weeks 16 and 32, with additional interim DTSQ measurements.RESULTS -For all patients combined, the mean baseline present QoL score was 1.3, reflecting "good" QoL. Present QoL improved with glargine ϩ lispro but did not change with NPH ϩ human insulin (1.6 Ϯ 0. CONCLUSIONS -Insulin glargine plus insulin lispro improves treatment satisfaction, reduces the negative impact of diabetes on QoL, and improves QoL in comparison with NPH insulin plus unmodified human insulin in type 1 diabetes.

Clinical and Sociodemographic Predictors of the Quality of Life among Patients with Type 2 Diabetes Mellitus on the East Coast of Peninsular Malaysia

“…However, some studies have demonstrated that the initiation of insulin did not impair the QoL; in fact, there are studies showing an improvement in the QoL instead (27)(28)(29)(30). These contradictory findings may be related to the different types of insulin (human insulin versus analogues), delivery systems (multiple injections versus continuous pump) and insulin regimens ('before bed' insulin, twice daily insulin or basal bolus insulin) (1,14).…”

Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes

“…To evaluate changes in gastrointestinal symptoms, patients were asked to fill in the Gastrointestinal Symptom Rating Scale (GSRS) score [17], a validated survey of gastrointestinal symptoms (abdominal pain, reflux, indigestion, diarrhea, and constipation) at each visit. The patients were also asked to complete the Diabetes Treatment Satisfaction Questionnaire (DTSQ) [19] and the Diabetes Medication Satisfaction Questionnaire (DiabMedSat) [20] to assess treatment satisfaction at weeks 0 and 24.…”

Utilities and disutilities for attributes of injectable treatments for type 2 diabetes

“…Most injectable treatments for type 2 diabetes must be administered at a time coordinated with meals. For example, human shortacting insulin must be administered within 30 min prior to eating [25][26][27][28][29]. Other medications have been developed that have a more flexible dosing regimen, allowing for injections at any time of day regardless of when a patient eats [16,30].…”